Nailing down another deal with its Tumor-Activated Prodrug (TAP) technology, ImmunoGen Inc. is getting $1 million up front and as much as $42 million in milestone payments from Biogen Idec Inc., which is researching antibodies to an undisclosed tumor-cell target. (BioWorld Today) Read More
